Open access
Jul 2026
Adapted XBB.1.5 vaccine effectiveness against severe COVID-19 outcomes among immunocompromised persons in 2023-24 in six European countries: a VEBIS-EHR network study.
BACKGROUND We estimated the XBB.1.5 vaccine effectiveness (VE) against COVID-19 hospitalization and death in Belgium, Denmark, Italy, Portugal, Spain (Navarre), and Sweden following the 2023-24 fall vaccination campaign among immunocompromised persons (ICPs). RESEARCH DESIGN AND METHODS We conducted a multi-country r...
A. Blake, J. Humphreys, K. Olson et al.
· Expert Review of Vaccines · 0 citations